UroStream

In recent years, some immunotherapy approaches for renal cancer have faced setbacks, failing to meet primary endpoints. However, with ongoing advancements in targeted therapy, immunotherapy, and other treatment modalities, significant progress has been made in managing advanced renal cancer. Notably, the success of multiple large-scale Phase III trials on targeted and immunotherapy combinations has marked the beginning of a new era in first-line treatment for advanced renal cancer. In 2024, several major breakthroughs were achieved. To provide deeper insights, Oncology Frontier invited Xinan Sheng, professor at Peking University Cancer Hospital, to summarize the key research developments that may serve as valuable references for future renal cancer treatment and research.

As 2024 concludes, the field of minimally invasive urological surgery has made remarkable strides, particularly in prostate cancer surgery, which often serves as a testing ground for innovative surgical approaches. With the advancement of precision medicine and multidisciplinary team (MDT) management, prostate cancer surgery now extends beyond simple tumor removal, incorporating preoperative diagnostic optimization, postoperative systemic therapy, and alternative local treatment approaches. In this annual review, Dr. Yao Zhu from Fudan University Shanghai Cancer Center summarizes the key developments in prostate cancer surgery over the past year.

Editorial Note: The ESMO Asia 2024 conference, hosted recently in Singapore, provided a platform for in-depth discussions on advancements in oncology. During the event, Urology Frontier had the opportunity to…

Radical cystectomy remains the standard treatment for muscle-invasive bladder cancer (MIBC), but many patients express a strong desire to preserve their bladder. To address this, various bladder-sparing strategies have been explored, including transurethral resection of bladder tumor (TURBT), partial cystectomy (PC), chemotherapy, radiotherapy, and surveillance. At the recent ESMO Asia Annual Meeting, Professor Ming Cao from Renji Hospital, Shanghai Jiao Tong University School of Medicine, presented his research on bladder preservation through postoperative adjuvant therapy for MIBC. Urology Frontier had the opportunity to discuss his findings with him on-site.

As 2024 draws to a close, the field of oncology celebrates the year’s grand finale with the ESMO ASIA Annual Meeting. The conference not only attracted top scholars and researchers from across Asia and the global oncology community but also showcased numerous breakthroughs in urologic oncology. On-site at the conference, Urology Frontier invited Professor Xuefeng Qiu from Nanjing Drum Tower Hospital，The Affiliated Hospital of Nanjing University Medical School to summarize this year’s advancements in the field of prostate cancer, share his team’s research selected for ESMO ASIA, and discuss future trends in the field.

Translocation renal cell carcinoma (TRCC), though rare, constitutes a significant proportion of kidney cancer cases among young and middle-aged patients. Analyzing its characteristics in depth can aid in accurate diagnosis, treatment planning, and prognosis evaluation. At the 2024 ESMO Asia Annual Meeting in Singapore, a study by the team from Fudan University Shanghai Cancer Center on TRCC was showcased in a poster presentation. Urology Frontier invited Professors Hailiang Zhang and Xiaolin Lu to share key findings from their research.

Focusing on global progress while highlighting Chinese innovations, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Uro-Oncology Annual Meeting of the Sichuan Anti-Cancer Association were successfully held in Chengdu, Sichuan. Organized by the Sichuan Anti-Cancer Association and hosted by its Urological and Male Reproductive Tumors Committee in collaboration with the Department of Urology at West China Hospital, Sichuan University, the conference brought together experts to discuss the latest advancements. Following the event, Urology Frontier had the privilege of interviewing the conference’s executive chair, Dr. Hao Zeng, to explore the highlights of the meeting and the key areas for enhancing diagnostic and treatment capabilities for grassroots physicians in uro-oncolog

Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.

With economic development, lifestyle changes, and environmental factors, prostate cancer incidence in China has significantly increased. Screening high-risk populations and providing precision treatment and rehabilitation support based on patient characteristics are crucial for improving cure rates and quality of life. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Gang Zhu, Chair of the Urological Oncology Rehabilitation Committee of the Chinese Anti-Cancer Association and Director of General Surgery and Urology at United Family Healthcare, presented insights on individualized treatment for prostate cancer. Urology Frontier had the opportunity to delve deeper into this topic with Professor Zhu.